Search

Displaying results 4511 - 4520 of 6951 in total
  1. Drug

    Atopaxar

    go.drugbank.com/drugs/DB12046
    Investigational

    Atopaxar has been investigated for the treatment of Coronary Artery Disease and Acute Coronary Syndrome.

  2. Drug

    AZD-7762

    go.drugbank.com/drugs/DB12242
    Investigational

    AZD7762 has been investigated for the treatment of Cancer, Solid Tumors, and Advanced Solid Malignancies.

  3. Drug

    Dapivirine

    go.drugbank.com/drugs/DB08639
    Investigational

    Dapivirine has been investigated for the prevention of HIV-1 Infections and Topical Penile Exposures.

  4. Drug

    Epirizole

    go.drugbank.com/drugs/DB08991
    Experimental

    Epirizole is an oral nonsteroidal anti-inflammatory drug (NSAID) used for muscle and joint pain.

  5. Drug

    UDP-alpha-D-glucuronic acid

    go.drugbank.com/drugs/DB03041
    Experimental

    A nucleoside diphosphate sugar which serves as a source of glucuronic acid for polysaccharide biosynthesis. … In animals, UDP glucuronic acid is used for formation of many glucosiduronides with various aglycones. [PubChem]

  6. Drug

    Otamixaban

    go.drugbank.com/drugs/DB06635
    Investigational

    It is currently being developed by the French pharmaceutical company Sanofi-Aventis as a treatment for acute coronary syndrome.

  7. Drug

    Felypressin

    go.drugbank.com/drugs/DB00093
    Investigational

    It is a non-catecholamine vasoconstrictor used in local anaesthetic injections for dental use, and is an ingredient of preparations that have been used for treatment of pain and inflammation of the mouth

  8. Drug

    Tandutinib

    go.drugbank.com/drugs/DB05465
    Investigational

    MLN518 is a novel, oral, small molecule designed to inhibit type III receptor tyrosine kinases, including FLT3, (platelet-derived growth-factor receptor) PDGFR and c-KIT.

  9. Drug

    Calcium phosphate dihydrate

    go.drugbank.com/drugs/DB14481
    Approved

  10. Drug

    Orforglipron

    go.drugbank.com/drugs/DB18964
    ApprovedInvestigational

    [L56123] On April 1, 2026, the US FDA granted approval to orforglipron for use alongside diet and exercise to aid in weight reduction in certain patient populations. … Orforglipron is a first-in-class oral, non-peptide glucagon-like peptide-1 (GLP-1) receptor agonist.